参考文献/References:
[1] RUPERT R A,GRETCHEN A S,RICHARD A W,JENNIFER L S,SETH R F,HOLLY P,et al.Causes of vision loss worldwide,1990-2010:a systematic analysis[J].Lancet Glob Health,2013,1(6):e339-349.
[2] STITT A W,CURTIS T M,CHEN M,MEDINA R J,MCKAY G J,JENKINS A,et al.The progress in understanding and treatment of diabetic retinopathy [J].Prog Retin Eye Res,2016,51:156-186.
[3] TAKAHASHI T,KALKA C,MASUDA H,CHEN D,SILVER M,KEARNRY M,et al.Ischemia and cytokine induced mobilization bone marrow-derived endothclial progenitor cells for neovascularization[J].Nat Med,1999,5(4):434-438.
[4] TOSHINORI M,OREN M T,MARCY S,HONG M,DOUGLAS W L,JEFFERY M I,et al.Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor induced neovascularization in vivo [J].Exp Hematol,2002,30(8):967-972.
[5] ADAMIS A P,MILLOR J W,BERNAL M T,D’AMICO D J,FOLKMAN J,YEO T K,et al.Increased vascular endothelial growth factor levels in the vireous of eyes with proliderative diabetic retinopathy[J].Am J Ophthalmol,1994,118(4):445-450.
[6] RODRIGUES M,XIN X B,JEE A,BABAPOOR-FARROKHRAN S,KASHIWABUCHI F,MA T,et al.VEGF secreted by hypoxic Miller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy[J].Diabetes,2013,62:3863-3873.
[7] ZHANG W,YAN H.Simvastatin increases circulating endothelial progenitor cells and reduces the formation and pro gression of diabetic retinopathy in rats[J].Exp Eye Res,2012,105:1-8.
[8] ASAHARA T,MUROHARA T,SULLIVAN A,SILVER M,ZEE R,LI T,et al.Isolation of putative progenitor endothelial cells for Angiogenesis[J].Science,1997,275(5302):964-967.
[9] YI M,WU Y,LONG J,LIU F,LIU Z,ZHANG Y H,et al.Exosomes secreted from osteocalcin-overexpressing endothelial progenitor cells promote endothelial cell angiogenesis[J].Am J Physiol Cell Physiol,2019,317(5):C932-C941.
[10] LIEW A,MCDERMOTT J H,BARRY F,O’BRIEN T.Endothelial progenitor cellsfor the treatment of diabetic vasculopathy:panacea or Pandora’s box[J].Diabetes Obes Metab,2008,10(5):353-366.
[11] ADDELI B B,LUIZ G A,FABIANE B,PAULO B,MARCO A S,ALEXANDRA C S,et al.Systemic infusion of expanded CD133(+) cells and expanded CD133(+) cell-derived EVs for the treatment of ischemic cardiomyopathy in a rat model of AMI[J].Stem cells Int,2019,2019:4802578.
[12] GAZYAKAN E,HIRCHE C,REICHENBERGER M A,URBACH O,GERMANN G,ENGEL H.Modulation of nitric Oxide bioavailability attenuates ischemia-reperfusion injury in type II diabetes[J].J Plast Reconstr Aesthet Surg,2021,74(1):183-191.
[13] IGATO M,FADINI G P.Circulating stem/progenitor cells as prognostic biomarkers in macro-and microvascular disease:a narrative review of prospective observational studies [J].Curr Med Chem,2018,25(35):4507-4517.
[14] ZHANG S J,CHEN X,LI C P,LI X M,LIU C,LIU B H,et al.Identification and characterization of circular RNAs as a new class of putative biomarkers in diabetes retinopathy[J].Invest Ophthalmol Vis Sci,2017,58:6500-6509.
[15] WANG L,SHI Q,CAI Y,CHEN Q,GUO X Y,LI Z Y.Mechanical-chemical coupled modeling of bone regeneration within a biodegradable polymer scaffold loaded with VEGF[J].Biomech Model Mechanobiol,2020,19(6):2285-2306.
[16] LOUKOVAARA S,ROBCIUE A,HOLOPAINEN J M,LEHTI K,PESSI T,LIINAMAA J,et al.Ang-2 upregulation correlates with increased levels of MMP-9,VEGF,EPO and TGFβ1 in diabetic eyes undergoing vitrectomy[J].Acta Ophthalmol,2013,91(6):531-539.
[17] DUGEL P U,SINGH R P,KOH A,OGURA Y,WEISSGERBER G,GEDIF K,et al.HAWK and HARRIER ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration[J].Ophthalmology,2021,128(1):89-99.
[18] ELLENRIEDER V,ALBER B,LACHER U,HENDLER S F,MENKE A,BOECK W,et al.Role of MT-MMPs and MMP-2 in pabcreatic cancer progression[J].Int J Cancer,2010,85(1):14-20.
[19] ZHANG D,QIU X,LI J H,ZHENG S H,LI L W,ZHAO H C.TGF-β secreted by tumor-associated macrophages promotes proliferation and invasion of colorectal cancer via MiR-34a-VEGF axis[J].Cell Cycle,2018,17(24):2766-2778.
相似文献/References:
[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[6]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[7]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[8]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[9]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[10]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.